INVA news

Latest 1 stories · newest Aug 5, 2026

INVA

Innoviva Q2 2026 revenue up 19%

Innoviva reported Q2 2026 revenue of $119.6 million, increasing 19% year-over-year, driven by its royalty portfolio and net product sales growth from its IST platform. The company also launched Nortiva Bio and announced a licensing agreement with Dr. Reddy's Laboratories.

Earnings Aug 5, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same INVA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/INVA/newsSTART FREE